Published in Biochim Biophys Acta on February 09, 1999
The axonal transport of mitochondria. J Cell Sci (2005) 5.19
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
A possible site of superoxide generation in the complex I segment of rat heart mitochondria. J Bioenerg Biomembr (2005) 1.28
TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells. J Biol Chem (2004) 1.18
Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. J Biol Chem (2003) 1.16
The interactions of flavonoids within neuronal signalling pathways. Genes Nutr (2007) 1.11
Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol (2010) 1.01
DNA alteration and programmed cell death during ageing of sunflower seed. J Exp Bot (2011) 0.96
Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One (2010) 0.96
Tributyltin interacts with mitochondria and induces cytochrome c release. Biochem J (2001) 0.89
Mitochondrial disorders. Biochim Biophys Acta (1999) 0.88
Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein. PLoS One (2012) 0.85
The role of caspase activation and mitochondrial depolarisation in cultured human apoptotic eosinophils. Saudi J Biol Sci (2010) 0.84
AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell Mol Neurobiol (2012) 0.81
Neurosupportive Role of Vanillin, a Natural Phenolic Compound, on Rotenone Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells. Evid Based Complement Alternat Med (2015) 0.80
New evidence on iron, copper accumulation and zinc depletion and its correlation with DNA integrity in aging human brain regions. Indian J Psychiatry (2010) 0.77
Shedding light on mitochondrial function by real time monitoring of NADH fluorescence: I. Basic methodology and animal studies. J Clin Monit Comput (2012) 0.76
Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice. Clin Interv Aging (2015) 0.76
Synergistic effects of amyloid peptides and lead on human neuroblastoma cells. Cell Mol Biol Lett (2012) 0.75
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med (2001) 6.07
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Understanding cell death in Parkinson's disease. Ann Neurol (1998) 2.16
Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol (2009) 2.13
Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (1996) 2.05
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med (1999) 2.00
Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci (2000) 1.97
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med (1989) 1.59
Levodopa motor complications in Parkinson's disease. Trends Neurosci (2000) 1.58
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord (1993) 1.48
The core assessment program for intracerebral transplantation. Mov Disord (1995) 1.47
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet (2004) 1.42
Progressive dementia and gait disorder in a 78 year old woman. J Neurol Neurosurg Psychiatry (2000) 1.39
Levodopa: why the controversy? Lancet (2002) 1.39
High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol (1997) 1.36
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol (1999) 1.22
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol (1998) 1.22
Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol (1996) 1.21
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol (2000) 1.18
Manganese intoxication and chronic liver failure. Ann Neurol (1994) 1.18
The evolution and origin of motor complications in Parkinson's disease. Neurology (2000) 1.15
Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res (1992) 1.14
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol (1995) 1.13
A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol (1998) 1.11
Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest (1984) 1.08
Occupation and parkinsonism in three movement disorders clinics. Neurology (2005) 1.08
Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res (2000) 1.07
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci (1996) 1.04
Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol (1996) 1.04
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord (1998) 1.03
No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis. Neurology (1981) 1.01
A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data. Neuropsychiatry Neuropsychol Behav Neurol (2000) 1.01
Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol (1998) 0.99
Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant (1997) 0.99
A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann Surg (1982) 0.99
Development of dopaminergic neurons in the human substantia nigra. Exp Neurol (1991) 0.96
Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol (2004) 0.95
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm (Vienna) (2004) 0.93
Dopamine receptors: from structure to behavior. Trends Neurosci (2000) 0.92
Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol (1997) 0.88
Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. Mov Disord (1999) 0.88
TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res (2000) 0.87
Autologous mixed lymphocyte reaction in patients with myasthenia gravis: correlation with disease activity. J Immunol (1984) 0.86
Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther (1998) 0.86
Thymectomy in late-onset myasthenia gravis. Arch Neurol (1982) 0.85
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD). J Neural Transm (Vienna) (2004) 0.85
The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. Cell Transplant (1995) 0.85
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 0.84
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem (1997) 0.84
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res (1994) 0.84
L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem (1997) 0.84
The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol (1998) 0.82
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. Mov Disord (2000) 0.82
Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res (1993) 0.82
The pathogenesis of myasthenia gravis--a hypothesis. Med Hypotheses (1981) 0.82
Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging (1996) 0.81
Infectious issues in human fetal neural transplantation. Cell Transplant (1998) 0.81
Dyskinesias assessment workshop: reports from the working groups. Mov Disord (1999) 0.80
The effects of salicylate on the pharmacokinetics of phenytoin. Neurology (1981) 0.80
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol (2009) 0.80
Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection. Neuroscience (2002) 0.79
Thymoma following transcervical thymectomy for myasthenia gravis. Ann Thorac Surg (1983) 0.79
Treatment with fetal allografts. Neurology (1997) 0.79
Phenytoin: pharmacokinetics and clinical therapeutics. Neurosurgery (1981) 0.79
Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol (1994) 0.79
Myasthenia gravis. Surg Clin North Am (1980) 0.78
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease. Neurology (1991) 0.78
Neonatal myasthenia gravis in the infant of an asymptomatic thymectomized mother. Can J Neurol Sci (1982) 0.78
The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology (2000) 0.78
Effect of thymectomy on peripheral lymphocyte subsets in myasthenia gravis: selective effect on T-cells in patients with thymic atrophy. J Immunol (1983) 0.78
The role of surgery in Parkinson's disease management. Neurology (1994) 0.77
Magnetic resonance imaging of neurodegenerative diseases. J Neuroimaging (1994) 0.77
GPi pallidotomy--have we made a dent in Parkinson's disease? Ann Neurol (1996) 0.77
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord (2003) 0.77
Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration. Biol Trace Elem Res (1997) 0.77
Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Mov Disord (1998) 0.77
Treatment of the "on-off" phenomenon in Parkinsonism with lithium carbonate. Ann Neurol (1982) 0.77
A double-blind controlled study of MK-486 in Parkinson's disease. Trans Am Neurol Assoc (1973) 0.76
The effect of plasmapheresis on post-thymectomy ocular dysfunction. Can J Neurol Sci (1981) 0.76
Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol (2001) 0.76
Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. J Neurochem (1999) 0.76
[Neurologic manifestations of hyperparathyroidism. Study of 120 cases]. Arq Neuropsiquiatr (1982) 0.76
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology (1993) 0.76
Iron induces degeneration of nigrostriatal neurons. Brain Res Bull (1992) 0.75
"On-off" syndrome treated with lithium carbonate: a case report. Am J Psychiatry (1981) 0.75
Early therapy for Parkinson's disease. Arch Neurol (1991) 0.75
Parkinsonism and amiodarone therapy. Ann Neurol (1989) 0.75
Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole. Neurology (2000) 0.75
Autologous adrenal medulla to caudate nucleus transplantation in advanced Parkinson's disease: 18 month results. Prog Brain Res (1990) 0.75
Familial benign intracranial hypertension and depression. Can J Neurol Sci (1982) 0.75
Toward the use of surgical placebo-controlled trials. Transplant Proc (1997) 0.75
Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica. Arch Neurol (1982) 0.75
On the mechanism of pathogenesis of human myasthenia gravis. Trans Am Neurol Assoc (1981) 0.75
Current concepts in the management of movement disorders. Clin Neurosurg (1981) 0.75